RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
1-Year Return
18.15%
This Quarter Return
+1.1%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$3.17B
AUM Growth
-$132M
(-4%)
Cap. Flow
+$189M
Cap. Flow
% of AUM
5.98%
Top 10 Holdings %
Top 10 Hldgs %
55.39%
Holding
52
New
18
Increased
15
Reduced
4
Closed
4
Top Buys
| 1 |
Axsome Therapeutics
AXSM
|
$90.4M |
| 2 |
Ascendis Pharma
ASND
|
$82.2M |
| 3 |
Exelixis
EXEL
|
$77.9M |
| 4 |
Alector
ALEC
|
$75.5M |
| 5 |
ZGNX
Zogenix, Inc.
ZGNX
|
$74.6M |
Top Sells
Sector Composition
| 1 | Healthcare | 93.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PRVL
26
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $39.5M | 1.25% |
3,240,534
-123,071
| -4% | -$1.5M |
|
27
Ardelyx
ARDX
$1.57B
| $36.5M | 1.15% |
6,416,684
+1,057,821
| +20% | +$6.01M |
|
28
Arcutis Biotherapeutics
ARQT
$2.06B
| $34.7M | 1.1% |
+1,165,184
| New | +$34.7M |
|
|
ADAP
29
Adaptimmune Therapeutics
ADAP
$10.9M
| $34.1M | 1.08% |
+12,541,888
| New | +$34.1M |
|
30
Crinetics Pharmaceuticals
CRNX
$3.35B
| $28.8M | 0.91% |
1,961,209
+86,000
| +5% | +$1.26M |
|
31
scPharmaceuticals
SCPH
$299M
| $26M | 0.82% |
3,518,998
+271,993
| +8% | +$2.01M |
|
|
TRIL
32
DELISTED
Trillium Therapeutics Inc.
TRIL
| $25.7M | 0.81% |
+6,361,446
| New | +$25.7M |
|
33
Stoke Therapeutics
STOK
$1.13B
| $25.6M | 0.81% |
1,119,963
| – | – |
|
34
Enliven Therapeutics
ELVN
$1.19B
| $23.3M | 0.74% |
+363,587
| New | +$23.3M |
|
35
Compugen
CGEN
$134M
| $21.5M | 0.68% |
+2,957,434
| New | +$21.5M |
|
|
IMGN
36
DELISTED
Immunogen Inc
IMGN
| $17.6M | 0.56% |
+5,166,303
| New | +$17.6M |
|
37
NovoCure
NVCR
$1.37B
| $17.4M | 0.55% |
+259,099
| New | +$17.4M |
|
|
CNCE
38
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $16.4M | 0.52% |
+1,858,474
| New | +$16.4M |
|
39
Solid Biosciences
SLDB
$428M
| $10.9M | 0.35% |
304,744
| – | – |
|
|
GRTX
40
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
| $8.49M | 0.27% |
893,115
-161,063
| -15% | -$1.53M |
|
41
X4 Pharmaceuticals
XFOR
$78.6M
| $6.02M | 0.19% |
20,076
+11,066
| +123% | +$3.32M |
|
42
Passage Bio
PASG
$22.8M
| $5.08M | 0.16% |
+16,132
| New | +$5.08M |
|
43
uniQure
QURE
$985M
| $3.9M | 0.12% |
+82,180
| New | +$3.9M |
|
44
ESSA Pharma
EPIX
$11M
| $3.84M | 0.12% |
959,300
-40,700
| -4% | -$163K |
|
|
PTLA
45
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $3.06M | 0.1% |
429,399
| – | – |
|
46
Cartesian Therapeutics
RNAC
$277M
| $2.1M | 0.07% |
+29,021
| New | +$2.1M |
|
47
Insmed
INSM
$30.7B
| $1.4M | 0.04% |
+87,405
| New | +$1.4M |
|
48
Vericel Corp
VCEL
$1.72B
| $917K | 0.03% |
+100,000
| New | +$917K |
|
49
Dynavax Technologies
DVAX
$1.18B
| – | – |
-2,365,912
| Closed | -$13.5M |
|
|
FTSV
50
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| – | – |
-1,933,250
| Closed | -$76.1M |
|